Overview

Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of different doses of CAT-2003 in patients with hyperlipidemia when CAT-2003 is taken for 4 weeks. The study will evaluate effects of CAT-2003 on (1) fasting triglycerides and non-HDL-C in patients with moderate hypertriglyceridemia and (2) fasting LDL-C levels in combination with a statin in patients with hypercholesterolemia who are on a statin.
Phase:
Phase 2
Details
Lead Sponsor:
Catabasis Pharmaceuticals
Treatments:
Hydroxymethylglutaryl-CoA Reductase Inhibitors